Literature DB >> 15519007

Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.

Giancarlo Marenzi1, Gianfranco Lauri, Emilio Assanelli, Jeness Campodonico, Monica De Metrio, Ivana Marana, Marco Grazi, Fabrizio Veglia, Antonio L Bartorelli.   

Abstract

OBJECTIVES: The aim of this research was to assess the incidence, clinical predictors, and outcome of contrast-induced nephropathy (CIN) after primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
BACKGROUND: Contrast-induced nephropathy is associated with significant morbidity and mortality after PCI. Patients undergoing primary PCI may be at higher risk of CIN because of hemodynamic instability and unfeasibility of adequate prophylaxis.
METHODS: In 208 consecutive AMI patients undergoing primary PCI, we measured serum creatinine concentration (Cr) at baseline and each day for the following three days. Contrast-induced nephropathy was defined as a rise in Cr >0.5 mg/dl.
RESULTS: Overall, CIN occurred in 40 (19%) patients. Of the 160 patients with baseline Cr clearance >/=60 ml/min, only 21 (13%) developed CIN, whereas it occurred in 19 (40%) of those with Cr clearance <60 ml/min (p < 0.0001). In multivariate analysis, age >75 years (odds ratio [OR] 5.28, 95% confidence interval [CI] 1.98 to 14.05; p = 0.0009), anterior infarction (OR 2.17, 95% CI 0.88 to 5.34; p = 0.09), time-to-reperfusion >6 h (OR 2.51, 95% CI 1.01 to 6.16; p = 0.04), contrast agent volume >300 ml (OR 2.80, 95% CI 1.17 to 6.68; p = 0.02) and use of intraaortic balloon (OR 15.51, 95% CI 4.65 to 51.64; p < 0.0001) were independent correlates of CIN. Patients developing CIN had longer hospital stay (13 +/- 7 days vs. 8 +/- 3 days; p < 0.001), more complicated clinical course, and significantly higher mortality rate (31% vs. 0.6%; p < 0.001).
CONCLUSIONS: Contrast-induced nephropathy frequently complicates primary PCI, even in patients with normal renal function. It is associated with higher in-hospital complication rate and mortality. Thus, preventive strategies are needed, particularly in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519007     DOI: 10.1016/j.jacc.2004.07.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  154 in total

1.  In-hospital prognostic value of hemoglobin levels on admission in patients with acute ST segment elevation myocardial infarction undergoing primary angioplasty.

Authors:  Cihan Dündar; Vecih Oduncu; Ayhan Erkol; Ali Cevat Tanalp; Dicle Sırma; Ali Karagöz; Can Yücel Karabay; Alev Kılıçgedik; Selçuk Pala; Kürşat Tigen; Akın Izgi; Cevat Kırma
Journal:  Clin Res Cardiol       Date:  2011-09-20       Impact factor: 5.460

2.  Epidemiology of contrast-associated acute kidney injury in ICU patients: a retrospective cohort analysis.

Authors:  Eric A J Hoste; Severine Doom; Jan De Waele; Louke J Delrue; Luc Defreyne; Dominique D Benoit; Johan Decruyenaere
Journal:  Intensive Care Med       Date:  2011-11-03       Impact factor: 17.440

3.  The risk of acute radiocontrast-mediated kidney injury following endovascular therapy for acute ischemic stroke is low.

Authors:  Y Loh; D L McArthur; P Vespa; Z-S Shi; D S Liebeskind; R Jahan; N R Gonzalez; S Starkman; J L Saver; S Tateshima; G R Duckwiler; F Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-03       Impact factor: 3.825

4.  Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease.

Authors:  Jan Matejka; Ivo Varvarovsky; Petr Vojtisek; Ales Herman; Vladimir Rozsival; Veronika Borkova; Jiri Kvasnicka
Journal:  Heart Vessels       Date:  2010-09-29       Impact factor: 2.037

5.  Comparison of magnetic wire navigation with the conventional wire technique for percutaneous coronary intervention of chronic total occlusions: a randomised, controlled study.

Authors:  Christian Roth; Rudolf Berger; Sabine Scherzer; Lisa Krenn; Clemens Gangl; Daniel Dalos; Georg Delle-Karth; Thomas Neunteufl
Journal:  Heart Vessels       Date:  2015-09-14       Impact factor: 2.037

6.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2013-08       Impact factor: 2.801

7.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Jpn J Radiol       Date:  2013-08       Impact factor: 2.374

Review 8.  Chronic kidney disease in acute coronary syndromes.

Authors:  Giancarlo Marenzi; Angelo Cabiati; Emilio Assanelli
Journal:  World J Nephrol       Date:  2012-10-06

Review 9.  Contrast-induced acute kidney injury in interventional cardiology: Emerging evidence and unifying mechanisms of protection by remote ischemic conditioning.

Authors:  Adebayo C Atanda; Oladipupo Olafiranye
Journal:  Cardiovasc Revasc Med       Date:  2017-06-06

Review 10.  [Iodinated contrast agent-induced nephropathy].

Authors:  C Erley
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.